Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085185581> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2085185581 abstract "We recruited 50 patients with T2-4 N0-2 M0 primary breast cancer into a phase I/II study to define the maximum tolerated dose (MTD), efficacy and tolerability of preoperative gemcitabine (1250 mg/m fixed dose) plus epirubicin (doses escalated from 90 mg/m) for 5 cycles followed by 4 cycles of docetaxel (scheduled fixed dose 100 mg/m) given on day 1 every 2 weeks (q2w) with pegfilgrastim support. The MTD for epirubicin was 100 mg/m, but the docetaxel dose had to be reduced to 80 mg/m. Dose-limiting toxicities included fatigue, stomatitis, diarrhea and dyspnea (all grade 3) during gemcitabine plus epirubicin, and fatigue (grade 3) and allergic reaction (grade 4) during docetaxel treatment, respectively. A pathologic complete response could be achieved in 13 patients (pT0+pTis, 26%), and in the breast and axilla in 12 patients [(pT0 or pTis)+pN0, 24%). Breast-conserving surgery (BCS) was possible in 35 patients (70%). Main grade 3/4 adverse events at MTD were fatigue (57/0%), leukopenia (27/8%), and liver (14/0%) and lung toxicity (14/0%). In conclusion, gemcitabine plus epirubicin 1250/100 mg/m q2w followed sequentially by docetaxel 80 mg/m q2w is highly effective as pre-operative chemotherapy with manageable toxicity. However, response and BCS rates could not be increased by administering gemcitabine plus epirubicin and docetaxel in a dose-dense fashion." @default.
- W2085185581 created "2016-06-24" @default.
- W2085185581 creator A5002219591 @default.
- W2085185581 creator A5004686505 @default.
- W2085185581 creator A5006518726 @default.
- W2085185581 creator A5007561826 @default.
- W2085185581 creator A5015984783 @default.
- W2085185581 creator A5059803147 @default.
- W2085185581 creator A5084545133 @default.
- W2085185581 creator A5089392438 @default.
- W2085185581 date "2005-10-01" @default.
- W2085185581 modified "2023-09-27" @default.
- W2085185581 title "Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial" @default.
- W2085185581 cites W1955382134 @default.
- W2085185581 cites W2013474338 @default.
- W2085185581 cites W2056115473 @default.
- W2085185581 cites W2091907178 @default.
- W2085185581 cites W2101760255 @default.
- W2085185581 cites W2109079833 @default.
- W2085185581 cites W2128985829 @default.
- W2085185581 cites W2133764807 @default.
- W2085185581 cites W2136738128 @default.
- W2085185581 cites W2139248078 @default.
- W2085185581 cites W2139510434 @default.
- W2085185581 cites W2142495011 @default.
- W2085185581 cites W2160450758 @default.
- W2085185581 cites W2162760540 @default.
- W2085185581 cites W2164361217 @default.
- W2085185581 cites W2164774797 @default.
- W2085185581 cites W2283438328 @default.
- W2085185581 cites W4233358210 @default.
- W2085185581 doi "https://doi.org/10.1097/01.cad.0000176508.73090.fb" @default.
- W2085185581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16162980" @default.
- W2085185581 hasPublicationYear "2005" @default.
- W2085185581 type Work @default.
- W2085185581 sameAs 2085185581 @default.
- W2085185581 citedByCount "11" @default.
- W2085185581 countsByYear W20851855812013 @default.
- W2085185581 crossrefType "journal-article" @default.
- W2085185581 hasAuthorship W2085185581A5002219591 @default.
- W2085185581 hasAuthorship W2085185581A5004686505 @default.
- W2085185581 hasAuthorship W2085185581A5006518726 @default.
- W2085185581 hasAuthorship W2085185581A5007561826 @default.
- W2085185581 hasAuthorship W2085185581A5015984783 @default.
- W2085185581 hasAuthorship W2085185581A5059803147 @default.
- W2085185581 hasAuthorship W2085185581A5084545133 @default.
- W2085185581 hasAuthorship W2085185581A5089392438 @default.
- W2085185581 hasConcept C121608353 @default.
- W2085185581 hasConcept C126322002 @default.
- W2085185581 hasConcept C143998085 @default.
- W2085185581 hasConcept C197934379 @default.
- W2085185581 hasConcept C2776694085 @default.
- W2085185581 hasConcept C2778375690 @default.
- W2085185581 hasConcept C2780258809 @default.
- W2085185581 hasConcept C2780835546 @default.
- W2085185581 hasConcept C2781190966 @default.
- W2085185581 hasConcept C530470458 @default.
- W2085185581 hasConcept C71924100 @default.
- W2085185581 hasConcept C90924648 @default.
- W2085185581 hasConceptScore W2085185581C121608353 @default.
- W2085185581 hasConceptScore W2085185581C126322002 @default.
- W2085185581 hasConceptScore W2085185581C143998085 @default.
- W2085185581 hasConceptScore W2085185581C197934379 @default.
- W2085185581 hasConceptScore W2085185581C2776694085 @default.
- W2085185581 hasConceptScore W2085185581C2778375690 @default.
- W2085185581 hasConceptScore W2085185581C2780258809 @default.
- W2085185581 hasConceptScore W2085185581C2780835546 @default.
- W2085185581 hasConceptScore W2085185581C2781190966 @default.
- W2085185581 hasConceptScore W2085185581C530470458 @default.
- W2085185581 hasConceptScore W2085185581C71924100 @default.
- W2085185581 hasConceptScore W2085185581C90924648 @default.
- W2085185581 hasLocation W20851855811 @default.
- W2085185581 hasLocation W20851855812 @default.
- W2085185581 hasOpenAccess W2085185581 @default.
- W2085185581 hasPrimaryLocation W20851855811 @default.
- W2085185581 hasRelatedWork W1974503127 @default.
- W2085185581 hasRelatedWork W2060666847 @default.
- W2085185581 hasRelatedWork W2315587357 @default.
- W2085185581 hasRelatedWork W2354357348 @default.
- W2085185581 hasRelatedWork W2376240298 @default.
- W2085185581 hasRelatedWork W2406160662 @default.
- W2085185581 hasRelatedWork W2439707001 @default.
- W2085185581 hasRelatedWork W2534899110 @default.
- W2085185581 hasRelatedWork W2591479921 @default.
- W2085185581 hasRelatedWork W4237503676 @default.
- W2085185581 isParatext "false" @default.
- W2085185581 isRetracted "false" @default.
- W2085185581 magId "2085185581" @default.
- W2085185581 workType "article" @default.